Ethnicity: High risk in Caucasians, and notably people of Eastern European (Ashkenazi) Jewish descent
- Abdominal pain
- Rectal bleeding
- Weight loss
- Signs of malnutrition
UC and Crohn’s disease (CD) share many of these symptoms,1-3 so it can be difficult for doctors to distinguish between these two inflammatory bowel diseases.
Complications of UC can include anaemia and pus production in the GI tract.2
Other complications of UC may include perforated bowel and toxic megacolon,4 which is an acute, non-obstructive dilation of the colon.
Both UC and CD can increase the risk of colorectal cancer (CRC):4
- The risk is related to the duration of the disease
- Risk is also linked to the extent (i.e. the length of the colon involved) and the severity of the disease
Several factors may contribute to the risk of developing IBD, including:5
Genetics: Family history – 5–20% of patients have a first-degree relative with IBD
Habitat: Those living in urban areas and industrial nations may be more likely to develop UC or CD than those in more rural areas
Diagnosis may involve a combination of the following tests and examinations.2
May be performed to check for anaemia, which may indicate bleeding in the intestines. Blood tests may also uncover a high white blood cell count, which is a sign of inflammation somewhere in the body.2
By testing a stool (faecal) sample, clinicians can tell if there is bleeding or infection in the intestines. Stool tests are commonly done to rule out other diseases of the GI tract, such as cancer.2
Magnetic resonance imaging (MRI) or computed tomography (CT) may be used to identify visible abnormalities in the gut.2
Flexible sigmoidoscopy and colonoscopy
These tests are performed using a long, flexible tube that has a small video camera on the end. A doctor can carefully examine the rectum, colon and small intestine for inflammation, bleeding, or ulcers, or may perform a biopsy. The tissue taken during a biopsy can be analysed microscopically to confirm a diagnosis.2
The management of IBD may involve medications, surgery, and nutritional support.
The general categories of drugs used in the treatment of UC2
- Aminosalicylates or 5-ASA (e.g. mesalazine) that reduce gut inflammation
- Steroids (e.g. prednisolone) that reduce gut inflammation
- Immunomodulators (e.g. azathioprine or 6-mercaptopurine or cyclosporine) that dampen the body’s immune responses that contribute to inflammation in the gut
- Biologic therapies (e.g. infliximab, adalimumab or golimumab) that reduce gut inflammation
- JAK Inhibitors (e.g. Tofacitanib)
Surgery may be necessary to relieve symptoms when people do not respond to medications or if complications occur. Partial or total removal of specific sections of the colon or rectum may be necessary.2
Diet and Nutrition
Proper nutrition is also a part of managing both UC and CD, and it is important that patients follow a nutritious diet and avoid foods that may worsen their symptoms.2
If you have been prescribed Entyvio and get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible side effects not listed within this website or in the Patient Information Leaflet.
Adverse events should be reported. In the United Kingdom, reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Takeda on 01628 537900 or e-mail DSO-UK@takeda.com